X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
SPR206 is a novel, intravenously (IV) administered next-generation polymyxin antibiotic for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by MDR Gram-negative bacterial infections.
Lead Product(s): SPR206
Therapeutic Area: Infections and Infectious Diseases Product Name: SPR206
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2024
Details:
Spero has granted Pfizer the rights to develop, manufacture, and commercialize SPR206 in ex-U.S. and ex-Asia territories. SPR206 is a potentially best-in-class, novel polymyxin derivative that was designed to reduce the kidney toxicity in polymyxin B and colistin.
Lead Product(s): SPR206
Therapeutic Area: Infections and Infectious Diseases Product Name: SPR206
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 05, 2021
Details:
Spero grants Pfizer rights to develop, manufacture, and commercialize SPR206 in ex-U.S. and ex-Asia territories in exchange for potential development and commercial milestone payments and royalties.
Lead Product(s): SPR206
Therapeutic Area: Infections and Infectious Diseases Product Name: SPR206
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 30, 2021
Details:
The funding will support the further clinical development of SPR206, an IV-administered next-generation polymyxin product candidate derived from Spero’s potentiator platform that is being developed to treat serious MDR Gram-negative infections in the hospital setting.
Lead Product(s): SPR206
Therapeutic Area: Infections and Infectious Diseases Product Name: SPR206
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $23.0 million Upfront Cash: Undisclosed
Deal Type: Funding May 17, 2021
Details:
Under an amended license agreement with Spero Therapeutics, the relevant patents for SPR206 will be assigned to Everest in Greater China, South Korea and certain Southeast Asian countries (the "Territory").
Lead Product(s): SPR206
Therapeutic Area: Infections and Infectious Diseases Product Name: SPR206
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Everest Medicines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 18, 2021
Details:
Analysis of preliminary clinical trial in healthy volunteers suggests that SPR206 is well-tolerated at doses that are likely to be within a therapeutic range for target MDR Gram-negative bacterial infections.
Lead Product(s): SPR206
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
